Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis

Intern Med. 2017 Sep 1;56(17):2335-2338. doi: 10.2169/internalmedicine.8706-16. Epub 2017 Aug 10.

Abstract

The development of tumor lysis syndrome (TLS) in association with treatment for myeloproliferative neoplasms (MPNs) is relatively rare. We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor. She also exhibited a rapid reduction of spleen volume. Our present case suggests the potential risk of TLS development after ruxolitinib treatment, particularly in patients with massive splenomegaly.

Keywords: myelofibrosis; ruxolitinib; splenomegaly; tumor lysis syndrome.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / complications*
  • Nitriles
  • Polycythemia Vera / drug therapy*
  • Polycythemia Vera / etiology
  • Primary Myelofibrosis / complications*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / adverse effects*
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Spleen / pathology
  • Treatment Outcome
  • Tumor Lysis Syndrome / drug therapy*

Substances

  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib